Cargando…
Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy, and/or long-term androgen deprivation therapy are the recommended treatment options. However, subsequent...
Autores principales: | Frantzi, Maria, Hupe, Marie C., Merseburger, Axel S., Schanstra, Joost P., Mischak, Harald, Latosinska, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555799/ https://www.ncbi.nlm.nih.gov/pubmed/32878288 http://dx.doi.org/10.3390/diagnostics10090658 |
Ejemplares similares
-
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
por: Latosinska, Agnieszka, et al.
Publicado: (2018) -
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
por: Latosinska, Agnieszka, et al.
Publicado: (2020) -
Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings
por: Latosinska, Agnieszka, et al.
Publicado: (2016) -
CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
por: Frantzi, Maria, et al.
Publicado: (2019) -
Urinary CE-MS peptide marker pattern for detection of solid tumors
por: Belczacka, Iwona, et al.
Publicado: (2018)